Vivoryon Therapeutics Aktie

NeuKaufen Kaufen Verkaufen Verkaufen

Aktien-Sparplan anlegen Aktien-Sparplan anlegen

1,90 EUR -0,02 EUR -1,25 %

14:56:53

STU

1,96 EUR -0,04 EUR -1,90 %

28.11.2024

ASX

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Smartphone

Marktkap.52,03 Mio. EUR

Div. Rendite0,00%

WKNA2QJV6

ISINNL00150002Q7

SymbolVIVRF

Werbung

Vivoryon Therapeutics Aktien News

Sortieren:Datum Meistgelesen

19.04.23GlobeNewswireVivoryon Therapeutics N.V. Reports Full Year 2022 Financial Results and Highlights Operational Progress

14.04.23GlobeNewswireVivoryon Therapeutics N.V. to Report Full Year 2022 Financial Results and Operational Progress on April 19, 2023

28.03.23GlobeNewswireVivoryon Therapeutics N.V. Provides Progress Update on Varoglutamstat Clinical Development for the Treatment of Alzheimer's Disease

21.02.23GlobeNewswireVivoryon Therapeutics N.V. to Present at Upcoming Conferences

28.11.22EQS GroupEQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics to Present a Clinical Update on its Novel Oral Small Molecule Varoglutamstat at Clinical Trials on Alzheimer's Disease Conference (CTAD)

23.11.22EQS GroupEQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Successful Listing of 2,054,796 Shares

22.11.22EQS GroupEQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Third Quarter 2022 Financial Results and Highlights Operational Progress

14.11.22EQS GroupEQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report Q3 2022 Financial Results and Operational Progress on November 22, 2022

30.09.22EQS GroupEQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports H1 2022 Financial Results and Highlights Operational Progress

30.09.22EQS GroupEQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Successful Private Placement of up to EUR 30 Million

26.09.22EQS GroupEQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report H1 2022 Financial Results and Operational Progress on September 30, 2022

31.07.22EQS GroupDGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Preclinical Evidence of Combination Therapy Potential for Varoglutamstat in AD at AAIC 2022

23.06.22EQS GroupDGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Positive Independent Data Safety Monitoring Board Recommendation for Phase 2b Study of Varoglutamstat in AD

22.06.22EQS GroupDGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Outcome of Annual General Meeting 2022

15.06.22EQS GroupDGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Q1 2022 Financial Results and Highlights Operational Progress

08.06.22EQS GroupDGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report First Quarter 2022 Financial Results on June 15, 2022

11.05.22EQS GroupDGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Hold its Annual General Meeting on June 22, 2022

28.04.22EQS GroupDGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Full Year 2021 Financial Results and Highlights Operational Progress

21.04.22EQS GroupDGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report Full Year 2021 Financial Results and Operational Progress on April 28, 2022

20.04.22EQS GroupDGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Participate at Upcoming Investor Conferences

01.04.22EQS GroupDGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 21 Million

31.03.22EQS GroupDGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Launches Capital Increase by Way of Private Placement

07.03.22EQS GroupDGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference

04.01.22EQS GroupDGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Participate in Upcoming Investor Conferences

22.12.21EQS GroupDGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Receives FDA Fast Track Designation for Varoglutamstat in Early Alzheimer's Disease

Vivoryon Therapeutics News

Vivoryon Therapeutics News: auf dieser Seite finden Sie alle Vivoryon Therapeutics News und Nachrichten zur Vivoryon Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Vivoryon Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Vivoryon Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.